CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR T-cell therapy and critical care : A survival guide for medical emergency teams.
CAR T-cell therapy and critical care : A survival guide for medical emergency teams.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞经过基因工程改造,使T细胞能够攻击特定的癌细胞,并改善难治/复发性侵袭性B细胞恶性肿瘤患者的结局。迄今为止,已有几种CAR-T 细胞产品获批,其他具有类似适应症或扩展至其他恶性肿瘤的产品目前正在评估中。CAR-T 细胞治疗的副作用可能是严重甚至危及生命的免疫相关毒性,特别是细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)。因此,医疗急救团队(MET)越来越多地参与CAR-T 细胞接受者的评估和管理。本文描述了CAR-T 细胞治疗的原理,并总结了主要并发症及相应的治疗干预措施,旨在为MET提供一份生存指南,并提出管理算法。
Chimeric antigen receptor (CAR) T cells are genetically engineered to give T cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed aggressive B cell malignancies. To date, several CAR T cell products are approved and additional products with similar indication or extended to other malignancies are currently being evaluated.
Side effects of CAR T cell treatment are potentially severe or even life-threatening immune-related toxicities, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Consequently, medical emergency teams (MET) are increasingly involved in the assessment and management of CAR T cell recipients. This article describes the principles of CAR T cell therapy and summarizes the main complications and subsequent therapeutic interventions aiming to provide a survival guide for METs with a proposed management algorithm.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。